MSIntuit® CRC

A pre-screen approach for MSI from digitized H&E slides

Screening biomarker
Histology Data
AI Diagnostic Tool
Colorectal Cancer
40%
With a sensitivity of ~95%, MSIntuit CRC can help rule out 40% of CRC patients from reflex screening with standard MMR/MSI testing techniques.
Context

Microsatellite instability (MSI) is a genomic biomarker that plays an important role in the treatment of colorectal tumours (CRC) patients. MSI is predictive of response to immunotherapy across all solid tumors.

Methods

We developed MSIntuit, an AI based pre-screening tool for MSI detection of CRC from H&E WSI, and performed the first successful blind validation confirming its robustness for clinical applications.

Results

MSIntuit CRC reaches sensitivity comparable to gold standard methods (92-95%) while ruling out almost half of the MSS patients.

MSIntuit CRC is an interpretable model - it highlights the parts of the slide image used to make its predictions.

Impact

With a sensitivity of ~95%, MSIntuit CRC can help rule out 40% of CRC patients from reflex screening with standard MMR/MSI testing techniques.

CE IVD

Learn more about MSIntuit CRC